Literature DB >> 14708692

Entecavir, FTC, L-FMAU, LdT and others.

Maria Buti1, Rafael Esteban.   

Abstract

To summarize, the future of chronic hepatitis B therapy seems to be the combination of different drugs. Ideally, the optimal drugs to combine would meet the following criteria: they should be orally applicable, they should have an excellent safety profile and the duration of therapy should limited. Currently, the drugs most likely to fulfill these criteria are the nucleoside analogs.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14708692     DOI： 10.1016/s0168-8278(03)00316-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


  5 in total

1.  Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase.

Authors:  Cecilia Carnrot; Liya Wang; Dimitri Topalis; Staffan Eriksson
Journal:  Protein Sci       Date:  2008-06-03       Impact factor: 6.725

2.  Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Authors:  Raymond F Schinazi; Leda Bassit; Marcia M Clayton; Bill Sun; James J Kohler; Aleksandr Obikhod; Alla Arzumanyan; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

3.  Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT.

Authors:  Ryuichi Nishii; Andrei Y Volgin; Osama Mawlawi; Uday Mukhopadhyay; Ashutosh Pal; William Bornmann; Juri G Gelovani; Mian M Alauddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-04       Impact factor: 9.236

4.  Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells.

Authors:  Rong Hu; Ling Li; Bart Degrève; Ginger E Dutschman; Wing Lam; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.938

Review 5.  Antivirals and antiviral strategies.

Authors:  Erik De Clercq
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.